Abciximab
Based on 2 publication(s) in Google Scholar
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 143653-53-6
- Molecular Weight:47.62 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Abciximab
More
Biological Activity
Fab-G1-kappa
Human
ITGA2B_ITGB3
Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin[2].
Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats weighing 200-250 g, balloon angioplasty model[2]
-
Dosage:0.25 mg/kg/day
-
Administration:Intravenous injection, 28 days
-
Result:Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB2 concentration.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab-G1-kappa
ELISA, FACS, Functional assay
-
Loaded Abciximab on Fab2G biosensor, can bind Integrin alpha 2B beta 3 Protein, Human (HEK293, His, HY-P77716) with an affinity constant of 2.475E-09 M as determined in BLI assay.
Chemical Information
-
CAS No. 143653-53-6
-
Appearance Liquid
-
Molecular Weight 47.62 kDa
-
Color Colorless to light yellow
-
SMILES
[Abciximab]
-
Synonyms
C7E3
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Am J Respir Cell Mol Biol
GP IIb/IIIa-ICAM-1 Mediated Platelet-Endothelial Adhesion Exacerbates Pulmonary Hypertension. [Abstract]2025 Feb 28. PMID: 40019848 -
Blood Vessel Thromb Hemost
Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents. [Abstract]2025 Jul 18;2(4):100096. PMID: 41030610
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. [Content Brief]
[2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz